STOCK TITAN

Mainz Biomed N.V. Ordinary Shares - MYNZ STOCK NEWS

Welcome to our dedicated page for Mainz Biomed N.V. Ordinary Shares news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed N.V. Ordinary Shares stock.

Mainz Biomed N.V. (symbol: MYNZ) is a pioneering company in the field of molecular genetic diagnostics, dedicated to providing patient-friendly testing solutions for life-threatening conditions. With a mission to improve early detection rates and thereby save lives through science, Mainz Biomed develops market-ready products that are both accurate and easy to use.

One of their key innovations is ColoAlert®, a non-invasive, at-home screening test for colorectal cancer (CRC). Utilizing real-time Polymerase Chain Reaction (PCR) to detect molecular-genetic biomarkers in stool samples, ColoAlert® offers high sensitivity and specificity. This test is available in select European countries and is poised for FDA approval in the United States through the ongoing 'ReconAAsense' clinical trial.

Mainz Biomed aims to expand its market reach by fostering partnerships with laboratories and healthcare providers. The company is also committed to advancing the early detection of other cancers, including pancreatic cancer, through products like PancAlert, which is currently in early stages of development.

Recently, Mainz Biomed showcased ColoAlert® at the UDH Congress, emphasizing its role in enhancing comprehensive health strategies. The company reported a 69% year-over-year revenue increase for ColoAlert® and maintained a stable financial condition with a $7.1 million cash balance at year-end.

In collaboration with healthcare professionals, Mainz Biomed continues to contribute to scientific research and knowledge exchange. This commitment was highlighted by their latest clinical studies, ColoFuture and eAArly DETECT, which demonstrated extraordinary statistical significance in CRC and advanced adenoma detection.

For more details, visit Mainz Biomed's official website at www.mainzbiomed.com.

Rhea-AI Summary
Mainz Biomed N.V. (MYNZ) to host HALLO DOC! event focusing on molecular genetics diagnostic solutions for early cancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. and Ganzimmun are hosting an educational webinar on Early Detection of Colorectal Cancer, focusing on innovative laboratory diagnostic options for screening. The event aims to provide insights on genetic markers and advancements in screening techniques for accurate risk assessment and early detection. Attendees can earn continuing education credits from ÄK and BDH. The webinar will be held on March 20, 2024, in German language, targeting pharmacists, physicians, and healthcare professionals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announces its participation at the 39th UDH Congress 2024, showcasing ColoAlert®, a cutting-edge colorectal cancer screening kit. The Company's commitment to advancing molecular genetics diagnostic solutions for early cancer detection is evident through its innovative technology and dedication to evidence-based healthcare practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
Rhea-AI Summary
Mainz Biomed partners with Trusted Health Advisors to advance FDA clinical trial for colorectal cancer screening test, aiming for market approval in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
partnership
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announces participation at the Gynecology Congress in Germany to showcase ColoAlert®, an innovative diagnostic solution for colorectal cancer screening. The company aims to connect with gynecologists, key players in CRC prevention, and establish ColoAlert® as a leading tool in early cancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) partners with Praxisdienst, Germany's largest online retailer, to distribute their innovative early cancer detection product ColoAlert®, enhancing healthcare delivery in Germany. The collaboration aims to provide a more comprehensive screening option for colorectal cancer, utilizing advanced technology for higher detection rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
partnership
Rhea-AI Summary
Mainz Biomed (NASDAQ: MYNZ) partners with TomaLab to launch ColoAlert® in Italy, revolutionizing colorectal cancer detection. ColoAlert® offers a highly effective at-home test for early cancer detection, improving survival rates in Italy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
partnership
-
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announces the opening of the 'European Oncology Lab' (EOL), a physician-led facility in Saarland, Germany, offering ColoAlert® as a laboratory medical service directly to physicians and patients. This expansion aims to make early colorectal cancer (CRC) detection more accessible for the approximately 8.7 million individuals covered by private health insurance in Germany. The new revenue growth opportunity is expected to complement the company's established commercial sales channels, coinciding with Colorectal Cancer Awareness Month in March.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary
Mainz Biomed N.V. (MYNZ) reaffirms its collaboration with TestDNA at the upcoming 10th Gdańsk Gastroenterology Symposium to advance innovative colorectal cancer detection in Poland. The company aims to increase treatment options and survival rates through early detection. Mainz Biomed and TestDNA will be present as exhibitors and open the second day of panel discussions. The symposium gathers national Polish lecturers, scientists, and practitioners to share the latest insights in gastroenterology, hepatology, and gastrointestinal endoscopy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) reported groundbreaking results from ColoFuture and eAArly DETECT studies, expanded international commercialization of ColoAlert®, and announced a year-end summary of corporate and product development progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
none

FAQ

What is the current stock price of Mainz Biomed N.V. Ordinary Shares (MYNZ)?

The current stock price of Mainz Biomed N.V. Ordinary Shares (MYNZ) is $6.68 as of December 20, 2024.

What is the market cap of Mainz Biomed N.V. Ordinary Shares (MYNZ)?

The market cap of Mainz Biomed N.V. Ordinary Shares (MYNZ) is approximately 12.3M.

What does Mainz Biomed specialize in?

Mainz Biomed specializes in developing molecular genetic diagnostic solutions for early detection of life-threatening conditions, such as colorectal and pancreatic cancers.

What is ColoAlert®?

ColoAlert® is Mainz Biomed's flagship product, a non-invasive, at-home test for colorectal cancer that uses PCR technology to detect molecular-genetic biomarkers in stool samples.

Where is ColoAlert® available?

ColoAlert® is currently available in select European countries and is undergoing FDA approval for the U.S. market.

What recent achievements has Mainz Biomed made?

Mainz Biomed recently presented significant clinical study results at the UDH Congress and reported a 69% year-over-year revenue increase for ColoAlert®.

What is the ReconAAsense trial?

The ReconAAsense trial is Mainz Biomed's FDA-registration study designed to evaluate ColoAlert® for U.S. regulatory approval.

What other products does Mainz Biomed have in development?

Apart from ColoAlert®, Mainz Biomed is developing PancAlert, an early-stage screening test for pancreatic cancer.

How does ColoAlert® differ from other CRC screening tests?

ColoAlert® offers higher accuracy and earlier detection rates compared to traditional fecal occult blood tests (FOBT), thanks to its advanced PCR-based technology.

What is Mainz Biomed’s mission?

Mainz Biomed's mission is to save lives through science by providing accurate, easy-to-use diagnostic solutions for early detection of deadly conditions.

How does Mainz Biomed contribute to the healthcare sector?

Mainz Biomed contributes through scientific research, innovative diagnostic solutions, and partnerships with healthcare professionals to improve early detection and patient care.

Where can I find more information about Mainz Biomed’s investor relations?

For more information on investor relations, visit Mainz Biomed’s official website at www.mainzbiomed.com/investors/.

Mainz Biomed N.V. Ordinary Shares

Nasdaq:MYNZ

MYNZ Rankings

MYNZ Stock Data

12.31M
3.26M
5.8%
0.25%
5.57%
Diagnostics & Research
Healthcare
Link
United States of America
Mainz